You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Agena has an ongoing partnership with Guangzhou-based DaRui to develop MassArray-based diagnostics for cancer and inherited diseases for the Chinese market.
The new factory will be the company’s first in vitro diagnostic reagent plant in the Asia Pacific region, producing clinical chemistry and immunoassay reagents.
The a single-tube, multiplex real-time PCR-based MeltPro High Risk HPV test identifies 14 high-risk genotypes of human papillomavirus and was previously CE marked.
Glycotest said it will use the funding for the planned US launch of its blood-based hepatocellular carcinoma test, which is based on a proprietary algorithm.
Some researchers believe that the use of microfluidics in the analysis of exosomes will help clinicians overcome the problem of heterogeneity in cancer cells.
The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.
The deal covers Cancer Genetics' microarray-based Tissue of Origin test, which analyzes 2,000 individual tumor genes to help identify a tumor's origin.
In the study, the POC assay produced a result in 15 minutes with comparable performance to a high-sensitivity laboratory assay in ruling out AMI.
The collaboration agreement includes support for development, regulatory submission, and commercialization of tests to guide use of Novartis' drug portfolio.
Molecular diagnostics revenues rose 5 percent driven in part by growth in infectious disease testing, a core area of diagnostic market focus for the firm.